Research programme: immune checkpoint modulators - Eli Lilly/Sanford-Burnham Medical Research Institute

Drug Profile

Research programme: immune checkpoint modulators - Eli Lilly/Sanford-Burnham Medical Research Institute

Latest Information Update: 30 Jun 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Eli Lilly; Sanford-Burnham Medical Research Institute
  • Developer Eli Lilly; Sanford Burnham Prebys Medical Discovery Institute
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Immunological disorders

Most Recent Events

  • 14 May 2015 Early research in Autoimmune disorders in USA (unspecified route)
  • 14 May 2015 Early research in Immunological disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top